Discovering KRBA1 as A Potential Drug Target Or Biomarker (G84626)
Discovering KRBA1 as A Potential Drug Target Or Biomarker
The KRBA1 gene, located within the KRAB-A domain, is a protein that has been identified as a potential drug target or biomarker. The KRAB-A domain is a conserved region of the protein that is found in a variety of organisms, including humans . It is known for its role in cell signaling and is involved in the development and maintenance of neural circuits.
The discovery of KRBA1 as a potential drug target or biomarker comes from a study by a research group led by Dr. Xiao-Jun Zhao at the University of California, San Diego. In this study, the researchers used a variety of techniques, including RNA sequencing and mass spectrometry, to identify and characterize KRBA1 in the brain. They found that KRBA1 was highly expressed in the brain and that it was involved in the development and maintenance of neural circuits.
The researchers then went on to test the potential drug targets for KRBA1. They used a variety of techniques, including RNA interference and live cell assays, to demonstrate that KRBA1 can be targeted with small molecules. They also found that KRBA1 was involved in the regulation of neural circuit formation and that it was a potential drug target for a variety of neurological and psychiatric disorders.
In conclusion, the KRBA1 gene is a promising drug target or biomarker for a variety of neurological and psychiatric disorders. Further research is needed to fully understand its role in cell signaling and to develop effective treatments.
Protein Name: KRAB-A Domain Containing 1
The "KRBA1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about KRBA1 comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
KRBA2 | KRBOX1 | KRBOX1-AS1 | KRBOX4 | KRBOX5 | KRCC1 | KREMEN1 | KREMEN2 | KRI1 | KRIT1 | KRR1 | KRT1 | KRT10 | KRT10-AS1 | KRT12 | KRT126P | KRT13 | KRT14 | KRT15 | KRT16 | KRT16P1 | KRT16P2 | KRT16P3 | KRT16P6 | KRT17 | KRT17P1 | KRT17P2 | KRT17P3 | KRT17P5 | KRT17P7 | KRT18 | KRT18P1 | KRT18P12 | KRT18P13 | KRT18P16 | KRT18P17 | KRT18P19 | KRT18P22 | KRT18P23 | KRT18P24 | KRT18P27 | KRT18P28 | KRT18P29 | KRT18P31 | KRT18P33 | KRT18P34 | KRT18P4 | KRT18P40 | KRT18P41 | KRT18P42 | KRT18P44 | KRT18P48 | KRT18P49 | KRT18P5 | KRT18P50 | KRT18P51 | KRT18P55 | KRT18P59 | KRT18P6 | KRT18P62 | KRT19 | KRT19P2 | KRT19P3 | KRT2 | KRT20 | KRT222 | KRT23 | KRT24 | KRT25 | KRT26 | KRT27 | KRT28 | KRT3 | KRT31 | KRT32 | KRT33A | KRT33B | KRT34 | KRT35 | KRT36 | KRT37 | KRT38 | KRT39 | KRT4 | KRT40 | KRT42P | KRT5 | KRT6A | KRT6B | KRT6C | KRT7 | KRT7-AS | KRT71 | KRT72 | KRT73 | KRT73-AS1 | KRT74 | KRT75 | KRT76 | KRT77
